Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR mutant lung cancer

Overview of attention for article published in Journal of Clinical Investigation, July 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
Good Attention Score compared to outputs of the same age and source (74th percentile)

Mentioned by

news: 3 news outlets

twitter: 11 X users

Readers on

mendeley: 31 Mendeley

So far, Altmetric has seen 12 X posts from 11 X users, with an upper bound of 70,181 followers.

🌸抄読会🌸By. Dr Tak🌸2023/2/13🌸 EGFR治療での初期増悪について #抄読会 Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer https://t.co/zZKS0MqZ4W

Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer: https://t.co/PeIdW7AcFI @UCSFMedicine #Oncology #Therapeutics https://t.co/kovnzTurOW

It is an exciting moment that our RBM10 paper is officially published in Journal of Clinical Investigation (JCI) now (https://t.co/0WWMzY9kIN).

RT @BivonaLabUCSF: Please read our latest work from @Shigeki04860554 out now in @jclinicalinvest: Inactivating genetic alteration of mRNA…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 8 additional X posts.